Workflow
Alkermes(ALKS)
icon
Search documents
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Zacks Investment Research· 2024-04-11 15:16
Core Insights - Alkermes plc announced positive top-line data from a phase Ib study for its oral orexin 2 receptor agonist, ALKS 2680, aimed at treating narcolepsy [1] - The study showed statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test across all tested doses [1][2] - Alkermes plans to initiate a phase II study for ALKS 2680 in narcolepsy type 2 (NT2) in the second half of 2024 [2] Study Details - The phase Ib study evaluated ALKS 2680 in narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics [1] - Doses tested in the study included 5 mg, 12 mg, and 25 mg, all showing clinically meaningful results [1][2] Market Context - If approved, ALKS 2680 could significantly change the treatment landscape for narcolepsy, although it may face competition from Axsome's Sunosi [2] - Axsome acquired U.S. rights to Sunosi in May 2022 and began marketing it shortly thereafter, with prior approval received in 2019 [3] - Jazz Pharmaceuticals also has a strong market presence with other sleep disorder drugs, Xyrem and Xywav [3]
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Seeking Alpha· 2024-04-09 20:29
MTStock Studio/E+ via Getty Images Alkermes Shows Strong Phase 1 Results for Narcolepsy Treatment ALKS-2680 Alkermes plc (NASDAQ:ALKS) stock hasn't moved much since my last update in November. Back then, I discussed its prospects in narcolepsy ahead of Phase 1 data for its orexin 2 receptor (OX2R) agonist, ALKS-2680. I highlighted the potential for this asset to be differentiated in that it addresses a cause of narcolepsy, rather than simply treating a symptom. I also discussed some historical downfalls of ...
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Prnewswire· 2024-04-09 11:00
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Dose-Dependent Effects and Pharmacodynamic Profile Support Advancement Into Planned Phase 2 Study — DUBLIN, April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline r ...
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Prnewswire· 2024-04-08 11:00
DUBLIN, April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients who received up to four years of treatment. LYBALVI is ap ...
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
Zacks Investment Research· 2024-04-02 17:16
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Alkermes (ALKS) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 24.90%.For the ...
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
Zacks Investment Research· 2024-03-13 17:46
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores ...
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Zacks Investment Research· 2024-03-12 14:50
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Zacks Investment Research· 2024-03-08 15:51
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...
Why Alkermes (ALKS) Outpaced the Stock Market Today
Zacks Investment Research· 2024-03-08 00:16
The most recent trading session ended with Alkermes (ALKS) standing at $29.45, reflecting a +1.76% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.34%, and the Nasdaq, a tech-heavy index, added 1.51%.The drugmaker's shares have seen an increase of 8.39% over the last month, surpassing the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21%.Market participants will be closely following the financial results of Alkerme ...
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Prnewswire· 2024-03-07 12:00
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. Alkermes Announces Appointment o ...